Live-attenuated Salmonella enterica serotype Choleraesuis vaccine with regulated delayed fur mutation confer protection against Streptococcus suis in mice

Yu-an Li
Yangzhou University

Yunyun Chen
Yangzhou University

Yuan zhao Du
State Key Laboratory of Genetically Engineered Veterinary Vaccines

Weiwei Guo
State Key Laboratory of Genetically Engineered Veterinary Vaccine

Juan Fan
Yangzhou Uni-Bio Pharmaceutical Co. Ltd

Matthew Bellefleur
University of Florida

Shifeng Wang
University of Florida

Huoying Shi (✉ hystg2017@163.com)
Yangzhou University  https://orcid.org/0000-0003-4128-329X

Research article

Keywords: Salmonella Choleraesuis, virulence, immunogenicity, Fur, inflammatory

Posted Date: August 30th, 2019

DOI: https://doi.org/10.21203/rs.2.13690/v1

License: ☇ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at BMC Veterinary Research on May 7th, 2020. See the published version at https://doi.org/10.1186/s12917-020-02340-4.
Abstract

Background: Recombinant Salmonella enterica serotype Choleraesuis (S. Choleraesuis) vaccine vector could be used to deliver heterologous antigens to prevent and control pig diseases. We have previously shown that a live-attenuated S. Choleraesuis vaccine candidate strain rSC0011 (ΔPcrp527::TT araC PBAD crp Δpmi-2426 ΔrelA199::araC PBAD lacI TT ΔasdA33, Δ, deletion, TT, terminator) delivering SaoA, a conserved surface protein that is present in many S. suis serotypes, provided excellent protection against S. suis challenge, but occasionally lead to morbidity (enteritidis) in vaccinated mice (approximately 1 in every 10 mice). Thus, alternated attenuation method was sought to reduce the reactogenicity of strain rSC0011. Herein, we described another recombinant attenuated S. Choleraesuis vector, rSC0012 (ΔPfur88:: TT araC PBAD fur Δpmi-2426 ΔrelA199:: araC PBAD lacI TT ΔasdA33) with regulated delayed fur mutation to avoid inducing disease symptoms while exhibiting a high degree of immunogenicity. Results: The strain rSC0012 strain with the ΔPfur88::TT araC PBAD fur mutation induced less production of inflammatory cytokines than strain rSC0011 with the ΔPcrp527::TT araC PBAD crp mutation in mice. When delivering the same pS-SaoA plasmid, the intraperitoneal LD50 of rSC0012 was 18.2 times higher than that of rSC0011 in 3-week-old BALB/C mice. rSC0012 with either pS-SaoA or pYA3493 was cleared from spleen and liver tissues 7 days earlier than rSC0011 with same vectors after oral inoculation. The strain rSC0012 synthesizing SaoA induced high titers of anti-SaoA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes) sites, as well as increased level of IL-4, the facilitator of Th2-type T cell immune response in mice. The recombinant vaccine rSC0012(pS-SaoA) conferred high percentage of protection against S. suis or S. Choleraesuis challenge in BALB/C mice. Conclusions: The live-attenuated Salmonella enterica serotype Choleraesuis vaccine strain rSC0012(pS-SaoA) with regulated delayed fur mutation provides a foundation for the development of a safe and effective vaccine against S. Choleraesuis and S. suis. Keywords: Salmonella Choleraesuis, virulence, immunogenicity, Fur, inflammatory

Background

Streptococcus suis is a pandemic pathogen responsible for a wide range of invasive diseases such as pneumonia, meningitis and bacteraemia in both humans and pigs[1,2]. S. suis type 2 (SS2) is the most frequently and virulent isolated from both humans and pigs among all serotypes reported to date [1,3]. The surface-anchored protein (Sao) is a highly conserved membrane-anchored protein and proved to be a immunogenic vaccine candidate[4]. However, Sao formulated with Emulsigen-Plus® provides only partial protection to mice against the SS2 infection [3]. In our previous study, a recombinant attenuated Salmonella enterica serotype Choleraesuis vaccine strain rSC0016 carrying saoA gene, provided full protection to mice against the SS2 challenge[5]. From the above, an effective delivery system such as live Salmonella enterica serotype Choleraesuis play a crucial role to the effectiveness of Sao.

The use of intracellular Salmonella enterica as a vehicle to deliver heterologous protective antigens against pathogens is an attractive strategy. Curtiss et al. developed the RDAS (Regulated Delayed Attenuated Strategies), which enable live salmonella vaccine effectively colonize lymphoid tissues during
the invasion stage because of its wild-type aggressiveness and then be full attenuated by silencing the virulence factor, while stimulate both strong cellular and humoral immunity in the immunized mice[6]. Several ways were used to implement this strategy (RDAS). One way is the reverse synthesis of lipopolysaccharide O-antigen by \textit{pmi} mutation [7]. Another way is to replace the upstream regulatory and promoter sequences of virulence genes with a tightly regulated \textit{araC P\textsubscript{BAD}} activator–promoter [8]. This strategy has been successfully used for \textit{S. Typhimurium} and \textit{S. Typhi}[6,7,8]. With this strategy, we construct a regulated delayed \textit{S. Choleraesuis} vaccine strain rSC0011 with regulated \textit{crp} and \textit{pmi} mutations[9]. rSC0011 delivering \textit{S. suis} antigens were effective to induce protective immunity against SS2 in mice, but it occasionally caused enteritidis.

We sought to improve our \textit{S. Choleraesuis} candidate vector vaccine by using alternative mutation or introducing new mutation to decreasing its potential to induce enteritidis and enhance immunogenicity. Fur is an important regulatory protein in \textit{Salmonella}. In the presence of iron, Fur acts as a repressor of iron-controlled genes and mounts an adaptive acid tolerance response [8]. Synthesis of Fur in a vaccine strain during growth confers acid tolerance and maintains iron homeostasis. A decrease of Fur synthesis in \textit{Salmonella} leads to acid sensitivity and iron acquisition [9]. Curtiss et al. reported that a \textit{S. Typhimurium} strain with an arabinose regulated \textit{fur} mutation is highly immunogenic [10]. In these consideration, an arabinose regulated \textit{fur} mutation (\textit{ΔP\textsubscript{fur}::TT araC P\textsubscript{BAD} fur}) was introduced into a \textit{S. Choleraesuis} vaccine strain with multiple preexist mutations (\textit{Δpmi–2426 ΔrelA199::araC P\textsubscript{BAD} lacI TT ΔasdA33}) to generate strain rSC0012. A plasmid \textit{pS-SaoA}[5], encoding \textit{saoA} from SS2, was transformed into this strain. We evaluated the virulence, immunogenicity and protection against challenge with virulent SS2 or \textit{S. Choleraesuis} C78–3.

\section*{Results}

\textit{Construction and characterization of the \textit{S. Choleraesuis} vaccine strain rSC0012}

Fur is a ferric uptake regulator that is involved not only in iron metabolism, uptake, and transport, but also invasion and survival of \textit{S. Typhimurium} in the hosts [11–13]. The absence of Fur attenuates \textit{S. Typhimurium}6,14]. To improve the safety and increase the immunogenicity of \textit{S. Choleraesuis} vector, a new strain, rSC0012, was generated with an arabinose regulated \textit{fur} \textit{ΔP\textsubscript{fur}::TT araC P\textsubscript{BAD} fur} (Figure 1A).

The phenotypes of the mutations \textit{ΔP\textsubscript{fur}::TT araC P\textsubscript{BAD} fur} and \textit{ΔrelA::araC P\textsubscript{BAD} lacI TT} were confirmed by western blot analysis (Figure 1B). The level of Fur synthesis decreased with arabinose dilution (Figure 1B). The presence of mutation \textit{ΔrelA::araC P\textsubscript{BAD} lacI TT} in rSC0012(\textit{pS-SaoA}) were confirmed by the increased synthesis of SaoA (Figure 1B) due to the derepression of \textit{P\textsubscript{trc}} promoter on plasmid in rSC0012, which resulted from reduced LacI production whose production was controlled by arabinose. The \textit{pmi} gene encodes 6-phosphomannose isomerase that interconverts fructose–6-phosphate and mannose–6-phosphate in \textit{Salmonella} [7].Because mannose is required for O-antigen synthesis, the \textit{Δpmi} mutation enables the strain rSC0012 to display a smooth LPS pattern in nutrient broth in the presence of mannose and a rough pattern in the absence of mannose (Figure 1C). The \textit{ΔasdA} mutation enables the strain
rSC0012 to have an obligate requirement for DAP [18], which can be complemented with a vector harboring the asd gene then eliminates the need for antibiotic resistance genes for plasmid maintenance [19]. The growth rates of rSC0012 with DAP, rSC0012(pS-SaoA), and rSC0012(pYA3493) were similar (Figure 1D). rSC0012 could grow only with DAP (Figure 1D).

**Antigen synthesis and plasmid stability in S. Choleraesuis rSC0012**

Stable maintenance of plasmids and the production of heterologous antigens are critical to ensure efficacy of recombinant live vaccines. The SaoA protein is a highly conserved surface protective antigen among *S. suis* serotypes [2, 5]. Using live attenuated *S. Choleraesuis* vector delivering SaoA antigen from *S. suis* will allow to develop a bivalent vaccine against both *S. Choleraesuis* and *S. suis*. The stabilities of pS-SaoA and pYA3493 in rSC0012 were evaluated by continuous culturing for 50 generations. The stabilities of both Asd+ plasmids, pS-SaoA and pYA3493, were 100% in rSC0012 (data not shown). All rSC0012 colonies examined (100 clones/generation) by endonuclease digestion possessed the Asd+ plasmid pS-SaoA or pYA3493. The 34-kDa SaoA protein was detected in cells obtained from both the first and 50th generations of rSC0012(pS-SaoA) (data not shown), indicating the stability of plasmid and stable synthesis of SaoA.

**Distribution of secreted SaoA in S. Choleraesuis rSC0012**

The production levels of SaoA in various subcellular fractions from pS-SaoA-carrying strains, rSC0011, rSC0012, and rSC0018, were determined (Figure 2A-B). rSC0018 is a derivative of C500 [5,20], a licensed live *S. Choleraesuis* vaccine attenuated by chemical methods in China, with an asdA mutation. The results showed that the level of the SaoA protein produced in the cytoplasm by strain rSC0012(pS-SaoA) was significantly lower than strain rSC0011(pS-SaoA) (Figure 2B; #, *P*<0.05), but significantly higher in supernatant when compared with rSC0011(pS-SaoA) and rSC0018(pS-SaoA) (Figure 2B; **, *P*<0.01). The SaoA protein produced in the periplasm fraction of rSC0012(pS-SaoA) was significantly higher than strain rSC0018(pS-SaoA)(Figure 2A-B).

**Lower virulence of S. Choleraesuis rSC0012 in vivo**

To evaluate the virulence of strains with mutations ΔP*{fur}*::TT araC P*BAD* fur or ΔP*{crp}*::TT araC P*BAD* crp, the LD*{50}* values of rSC0012 and rSC0011 were tested in 3-week-old BALB/c mice, which represents young mice. rSC0018 was used as an attenuation control. All strains carried the expression plasmid pS-SaoA. The results revealed that the LD*{50}*s of rSC0011(pS-SaoA), rSC0012(pS-SaoA), and rSC0018(pS-SaoA) were at least 10*{9}* CFU by oral inoculation; whereas, the LD*{50}* of wild-type C78–3 was 9.5×10*{2}* CFU (Table 2). Following intraperitoneal infection, the LD*{50}* of rSC0012(pS-SaoA) was 38.89-fold higher than that of rSC0011(pS-SaoA) and 3.2-fold higher than that of rSC0018(pS-SaoA) in 3-week-old mice. The LD*{50}* of rSC0012(pS-SaoA) was significantly higher than that of C78–3 and rSC0011(pS-SaoA), but similar to rSC0018(pS-SaoA) in 3-week-old mice (Table 2). These results indicated that the virulence of rSC0012(pS-
S. Choleraesuis vaccine strains harboring ΔP_{fur}::TT araC\textsubscript{BAD} fur was significantly lower than that of rSC0011(pS-SaoA) harboring ΔP_{crp}::TT araC\textsubscript{BAD} crp by intraperitoneal route in young mice.

**Tissue distribution of S. Choleraesuis strains in BALB/c mice**

Fur and Crp are important regulatory proteins in *Salmonella*. Inactivation of the *fur* and *crp* genes, attenuates the organism [6,21]. To quantitatively the colonization of the *S. Choleraesuis* strains containing regulated *fur* or *crp* mutations, 3-week-old BALB/c mice were orally inoculated with *rSC0011*(*pYA3493*), *rSC0012*(*pYA3493*), *rSC0018*(*pYA3493*), *rSC0011*(*pS-SaoA*), *rSC0012*(*pS-SaoA*), *rSC0018*(*pS-SaoA*), or wild-type *C78–3* (Figure 3A–F). The mice inoculated with wild-type *S. Choleraesuis* C78–3 died 3–5 days after inoculation, whereas the mice infected orally with vaccine strains *rSC0011*, *rSC0012*, *rSC0018* containing either plasmid pS-SaoA or pYA3493 survived. The bacteria titers of wild-type strain C78–3 in Peyer's patches, spleen, and liver were significantly higher than those of vaccine strains *rSC0011*, *rSC0012*, *rSC0018* containing either plasmid pS-SaoA or pYA3493 at 3 days after inoculation. (Figure 3A–C). The titers of bacteria in Peyer's patches were similar for strains *rSC0012*(*pYA3493*), *rSC0012*(*pS-SaoA*), *rSC0011*(*pYA3493*), and *rSC0011*(*pS-SaoA*) at 3–21 days post-inoculation(Figure 3A). At 3d, 7 d, 14 d, 21 d and 28 d, the numbers of *rSC0012*(*pS-SaoA*) were significantly higher than those of attenuated vaccine strains *rSC0018*(*pS-SaoA*), same for two control vector, the numbers of *rSC0012*(*pYA3493*) were significantly higher than those of attenuated vaccine strains *rSC0018*(*pYA3493*) and there was no significant difference with same strain with expression or control vector respectively (*P* < 0.01; Fig. 3A), indicating that the colonization abilities of strains *rSC0012*(*pS-SaoA*) and *rSC0012*(*pYA3493*) in Peyer's patches were higher than that of *rSC0018* with either pYA3493 or pS-SaoA.

In spleen, the titers of *rSC0012*(*pYA3493*) and *rSC0012*(*pS-SaoA*) were similar to those of vaccine strains *rSC0018*(*pYA3493*) and *rSC0018*(*pS-SaoA*) at 7, 14, 21, 28 days after inoculation (Figure 3B). The titers of strains *rSC0011*(*pYA3493*) and *rSC0011*(*pS-SaoA*) were significantly higher than those of *rSC0012*(*pYA3493*), *rSC0012*(*pS-SaoA*), *rSC0018*(*pYA3493*), and *rSC0018*(*pS-SaoA*), at 3, 7, 14, and 21 days, respectively (Figure 3B).

In liver, the titers of *rSC0012*(*pYA3493*) and *rSC0012*(*pS-SaoA*) were similar to those of vaccine strains *rSC0018*(*pYA3493*) and *rSC0018*(*pS-SaoA*) at 3, 14, 21, 28 days after inoculation (Figure 3C). At 3d, 7 d, 14 d, 21 d and 28 d post-inoculation, the titers of *rSC0012*(*pS-SaoA*) were significantly lower than those of *rSC0011*(*pS-SaoA*), same for two control vector, the numbers of *rSC0012*(*pYA3493*) were significantly lower than those of strains *rSC0011*(*pYA3493*).respectively (*P* < 0.01; Fig. 3C), whereas the strain *rSC0012*(*pYA3493*) was the fastest to be cleared in liver (Figure 3C). These results indicated that the ΔP_{fur}::TT araC\textsubscript{BAD} fur mutation impaired the colonization in the liver of *S. Choleraesuis* vaccine strains. In a summary, the ΔP_{fur}::TT araC\textsubscript{BAD} fur mutation reduced the colonization ability of *S. Choleraesuis* vaccine strains in mice spleen and liver but not in the Peyer's patches.

**Antibody responses in mice immunized with S. Choleraesuis strains**
All of the mice immunized with strains containing pS-SaoA developed anti-SaoA antibodies (Figure 4A). rSC0012(pS-SaoA) induced significantly higher anti-SaoA IgG titer than did rSC0011(pS-SaoA) 3 weeks after the immunization in 3-week-old mice (Figure 4A; *, P<0.05). Although the anti-SaoA IgG titer of rSC0012(pS-SaoA) were slightly higher than that of rSC0011(pS-SaoA) 5 weeks after immunization, they were not significantly different (Figures 4A). Compared to mice immunized with rSC0018(pS-SaoA), higher serum IgG titers against SaoA were detected in mice immunized with both rSC0011(pS-SaoA) and rSC0012(pS-SaoA) at 3 weeks and 5 weeks postimmunization (Figure 4A, *, P<0.05, **, P<0.01). After boosting, higher titers of anti-SaoA IgG were observed in mice immunized with all three strains containing pS-SaoA (Figure 4A, #, P<0.05). All three attenuated recombinant Salmonella strains induced significant OMP titers after the first immunization in mice (Figure 4B). A significant boosting of serum antibody responses to OMPs was observed after the second immunization, (Figure 4B; #, P<0.05).

Mucosal IgA anti-SaoA responses were detected at week 3 in mice immunized with all three attenuated strains containing pS-SaoA. rSC0018(pS-SaoA) induced lower titers of anti-SaoA IgA than rSC0012(pS-SaoA) or rSC0011(pS-SaoA) did in mice (Figure 4C, *, P<0.05, **, P<0.01). Anti-SaoA IgA levels detected in the rSC0012(pS-SaoA) immunized group were significantly higher than those induced in the rSC0011(pS-SaoA) immunized group at 3 and 5 weeks after the immunization (Figure 4C, *, P<0.05, **, P<0.01). These results indicated that strain rSC0012(pS-SaoA) harboring ΔPfur::TT araC BAD fur elicited a stronger immune response than strain rSC0011(pS-SaoA) harboring ΔPcrp::TT araC BAD crp did, especially elicit a stronger mucosal immune response.

**IFN-γ or IL–4 production induced by S. Choleraesuisstrains**

To further evaluate the effect of the ΔPfur::TT araC BAD fur and ΔPcrp::TT araC BAD crp mutations in a strain with multiple preexist mutations on Th1/Th2 immune responses, the levels of IFN-γ and IL–4 in the spleen tissues of mice 7 days and 14 days after booster immunization were measured. The results showed that the titers of IFN-γ and IL–4 induced in mice immunized with rSC0012, and rSC0011 with either pYA3493 or pS-SaoA were significantly higher than those induced in mice inoculated by strain rSC0018 with either pYA3493 or pS-SaoA at both 7 and 14 days after booster (Figure 5A, B; *, P<0.01,**, P<0.05). Although rSC0011(pS-SaoA) induced a slightly higher level of IFN-γ in mice than rSC0012(pS-SaoA) did, no significant difference was observed in 3-week-old mice at both 7 and 14 days after booster (Figure 5A-C). However, rSC0011(pYA3493) elicited a higher level of IFN-γ than rSC0012(pYA3493) did at 7 days after booster. The titers of IL–4 induced by rSC0012 with either pS-SaoA or pYA3493 in spleen tissues were significantly higher than those induced by rSC0011 with either pS-SaoA or pYA3493 in 3-week-old mice (Figure 5B; *, P<0.05, **, P<0.01) at 7 and 14 days after booster. Of note, rSC0012(pS-SaoA) induced a dominant Th2 immune response (IFN-γ < IL–4, IFN/IL–4<1) in 3-week-old mice (Figure 5C); whereas, rSC0011(pS-SaoA) elicited a moderately dominant Th1 immune response (IFN-γ > IL–4, IFN/IL–4>1) in 3-week-old mice (Figure 5C, *, P<0.05, **, P<0.01). These results indicated the isogenic strain with two different mutations, ΔPfur::TT araC BAD fur or ΔPcrp::TT araC BAD crp, affected different branches of immune responses. In additional, the titers of IFN-γ and IL–4 induced by the three attenuated strains harboring pS-SaoA in immunized mice were higher than those induced by the same strains...
harboring the emptor vector pYA3493 (Figure 5A–C; #, *P*<0.05, ##, **P**<0.01), suggesting that the protein, SaoA, might augment the immune responses in mice.

**Induction of inflammation in mice**

The inflammatory properties of intestinal tissue were investigated in mice after immuned vaccine strains and wild type strain, C78–3. The expression of cytokine genes, TNFα, IL–1β, IL–6 and IL–8, were assessed by quantitative real-time PCR in gut tissue samples at 6 hours and 12 hours postinfection. All strains with mutation ΔP*fur*::TT araC*P*BAD*fur* showed significantly lower transcription levels of cytokine genes IL–1β, IL–6, IL–8 and TNFα than the wild-type strain, C78–3 at both 6 h and 12 h postinfection (Fig 6A-D, *, *P*<0.05, **, **P**<0.01). The C78–3 with mutation ΔP*fur*::TT araC*P*BAD*fur* induced significantly lower transcription levels of cytokine genes IL–1β, IL–6, IL–8 and TNFα than the same strain with ΔP*crp* TT araC*P*BAD*crp* mutation at both 6 hours and 12 hours postinfection (Fig 6 C and D, &, **, &&, **P**<0.01). At 6 hours postinfection, strain rSC0012(pS-SaoA) showed significantly lower transcription levels of cytokine genes IL–1β, IL–6, IL–8 and TNFα than strain rSC0011(pS-SaoA) (Fig 6A), a similar trend was seen with IL–1β, IL–6, IL–8 and TNFα at 12 h, although the differences were not significant for IL–6 and TNFα (Fig 6B,#, *P*<0.05, ##, **P**<0.01). These results suggest that the addition of the ΔP*fur*::TT araC*P*BAD*fur* mutations could decreased the inflammatory potential of strains rSC0012(pS-SaoA).

**Comparison of the protective immunity induced by S. Choleraesuis strains**

To evaluate the protective immunity conferred by rSC0012(pS-SaoA), the mice in each immunized group were challenged orally with 50×LD$_{50}$ of the virulent *S. Choleraesuis* C78–3 strain or 20×LD$_{50}$ of the virulent SS2 strain at 14 days post-boost immunization. After challenge with C78–3, the results revealed 100% protection in mice immunized with either strain rSC0011(pS-SaoA) or strain rSC0012(pS-SaoA), suggesting full protection. Mice immunized with the rSC0018(pS-SaoA) strains resulted in 20% survival. In contrast, all the mice in the PBS group succumbed to the challenge after 4 days. There were no significant difference between the groups immunized with rSC0012(pS-SaoA) and rSC0011(pS-SaoA), though both displayed significantly higher levels of protection than the group immunized with rSC0018(pS-SaoA) (Figure 7A). After the SS2 challenge, immunization with the rSC0011(pS-SaoA), rSC0012(pS-SaoA) and rSC0018(pS-SaoA) strains resulted in 80% survival, 95% survival and 16.7% survival with the lethal SS2 challenge, respectively. In contrast, all the mice in the PBS group succumbed to the challenge after 2 days.

**Discussion**

The ultimate goal of an engineered live vaccine strain relies on achieving the proper balance between immunogenicity and attenuation [22,23]. Achieving that goal will restrict unacceptable reactogenicity to avoid over-excitation of inflammatory responses, but sufficient metabolic activity should be maintained to enable the live vaccine to reach deep lymphatic tissues and induce protective immunity [24]. Modern industry vaccine development relies on the genetic engineering of defined mutations in bacterial
strains[23,25,26]. In order to enhancing the immunogenicity of vaccine strains or to disarm them, multiple independent defined mutations were introduced into *Salmonella* to generate a new recombinant attenuated vaccine strains[6,25,23,27]. By incorporating proper mutations, vaccine strains can be rationally designed to to avoid unacceptable reactogenicity and enhanced immunogenicity [21]. Our previous *S. Choleraesuis* live attenuated vaccine vector rSC0011 occasionally caused enteritidis in mice[9]. One of the ways to address this problem is by incorporating a *sopB* mutation [5,25]. In this paper, another way to improve the *S. Choleraesuis* vector was reported.

Fur is an important regulatory proteins of *Salmonella*, which has been implicated in the acid tolerance response since *fur* mutants are acid sensitive and cause altered expression of several acid shock proteins [28,29]. A *S. Typhimurium* strain with an arabinose regulated *fur* mutation is adequately attenuated and highly immunogenic [6,30]. However, *S. Typhimurium* belong to group B, while *S. Choleraesuis* group C. Whether the Δfur::TT araC PBad fur mutation that results in the proper balance between attenuation and immunogenicity of *S. Typhimurium* is also appropriate for attenuated *S. Choleraesuis* vaccine has not been reported previously.

We corroborated the *S. Choleraesuis* strain rSC0012 (Δfur::TT araCPBad fur Δpmi ΔrelA::araCPBad lacI TT ΔasdA) displayed a regulated decrease of Fur production in the absence of arabinose. In a previous publication, *S. Typhimurium* strain with a single Δfur::TT araCPBad fur mutation has shown higher virulent than *S. Typhimurium* with a single Δcrp527::TT araCPBad crp mutation by an oral immunization. Unlike report from Curtiss et al in *S. Typhimurium* [6], our studies did not showed that the Δfur::TT araCPBad fur mutation has higher virulent than Δcrp527::TT araCPBad crp mutation in *S. Choleraesuis*. In fact, the LD₅₀ of rSC0012(pS-SaoA) was 38-fold higher than rSC0011(pS-SaoA) for 3-weeks-old mice with intraperitoneal injection. This result suggest that the *fur* mutation does different attenuation with *S. Choleraesuis* or *S. Typhimurium*, which may due to its complex role as a transcriptional activator of virulence in different strains [31].

The Δfur::TT araCPBad fur mutation can modify the iron regulated outer membrane protein, then strain with Δfur::TT araCPBad fur induced less inflammatory cytokine production in mice than the isogenic strain with Δcrp527::TT araCPBad crp mutation or wild type strain. Theses results suggest that the *S. Choleraesuis* with Δfur88::TT araCPBad fur mutation exhibits a lower propensity to elicit over-inflammatory responses while attenuated sufficiently.

Through the oral vaccination route, a vaccine strain will endure the challenges of acid, bile, and antimicrobial peptides existing in the gastrointestinal tract. Once inside Peyer’s patch, it will face macrophagocytes and T cells during the process transferring to deep lymphatic tissues [33]. Fe²⁺ is required for cellular function within nearly all cells, limiting the availability of Fe²⁺ starves pathogens for Fe²⁺ and weakens the pathogens’ ability to combat antimicrobial responses by the host[31,33]. Fur is a transcription factor which utilizes Fe²⁺ as a corepressor and represses siderophore synthesis in pathogens[34]. Thus, regulated delayed *fur* mutation may affect the growth of *S. Choleraesuis* in the deep
tissue of the mice. rSC0012, harboring mutation ΔP_{fur}::TT araC_{BAD} fur, was cleared more rapidly than rSC0011, harboring mutation ΔP_{crp}::TT araC_{BAD} crp, in the deeper lymphatic tissues, spleen, and liver of the immunized mice though both rSC0011 and rSC0012 had similar levels of Peyer's patch colonization by oral immunization. The clearance of rSC0012 in liver was similar to the attenuation control rSC0018. This result indicates that strain rSC0012 was more attenuated than rSC0011 in deep lymphoid tissue, which maybe due to preventive rSC0012 from getting iron in deep lymphoid tissue with regulated decreasing levels of Fur protein.

Both rSC0012 and rSC0011 induced higher levels of IgA, IgG, IFN-γ, and IL4 responses with great colonization compared to strain rSC0018 with less colonization in mice. In general, the live Salmonella vaccines with RDAS display superior colonization level in lymphoid tissues during the invasion stage, leading to enhanced protection by exposed to more Salmonella mycoprotein and heterologous antigens[10,35]. However, there do exist high levels of colonization but low immunogenicity. A strain with the regulated delayed rfc mutation exhibits superior colonization and yet does not stimulate higher heterologous protection than a Δrfc strain without RDAS[36]. Thus, in addition to colonization level, other determining factors may exist to induce the enhanced protection achieved by regulated delayed attenuation. From the above, Selecting the proper mutation is critical for vaccine development with RDAS. This study confirmed above statement. Although the colonization of strain rSC0012(pS-SaoA) in mice was less than that of strain rSC0011(pS-SaoA), strain rSC0012(pS-SaoA) stimulated stronger serum IgG and mucosal IgA responses than the strain rSC0011(pS-SaoA). This phenomenon suggests that strain with regulated delayed fur mutation may stimulate stronger antibody response with fewer bacteria than strain with regulated delayed crp mutation.

Both rSC0012 and rSC0011 aroused a Th1 cell-mediated response, as ostensived by the significant up-regulation of imprint Th1 cytokines, IFN-γ, the stimulator of Th1-type T cell immune response. It could partially be that the intracellular characteristics of Salmonella enterica cause them to be detected on the surface of APC through MHC. This phenomenon is consistent with previous studies with S. Typhi [6]. Strain rSC0012 induced higher Th2 cell-mediated response than strain rSC0011, as aroused by the significant up-regulation of imprint Th2 cytokines, IL-4 and greater humoral responses than rSC0011 in mice. The presence of S. suis-specific IgA serves to promptly deliver the antigen to Peyer's patch dendritic cells or phagocytes and also promptly excite the adaptive immunity during secondary exposure [37]. Quaintly, the more attenuated rSC0012 strain induced significantly higher IgA and IgG antibody responses to SaoA than the rSC0011 at 3 weeks after the initial immunization in juvenile mice, while in general live vaccine strains that are more attenuated are less immunogenic[21,27]. This may be due to a balance between attenuation and the ability to participation immune components and activate a controlled over-inflammatory response by the finely crafted strain[23].

The results presented herein highlight that strain rSC0012(pS-SaoA) with regulated delayed fur mutation has retained vaccine efficacy and adequate immunogenicity whilst being safer than previous strain rSC0011(pS-SaoA). Furthermore, the inclusion of the ΔP_{fur88}::TT araC_{BAD} fur mutation may be able to decrease inflammation caused by live-attenuated Salmonella enterica serotype Choleraesuis vaccine,
which has been an imperfection for other live-attenuated *Salmonella enterica* serotype Choleraesuis vaccine which transformed from wild type virulent strain. Both *S. Choleraesuis* and *S. suis* are major swine pathogens. Currently, there exist license live vaccines against *S. Choleraesuis* for swine, including Entersol® *Salmonella* T/C and SC−54 manufactured by Boehringer Ingelheim and Arugs SC/ST, respectively [38]. However, there is no licensed vaccine against *S. suis*. Preventing the diseases caused by *SS* in swine with a combined vaccine is a long-sought goal.

**Conclusions**

Our results have shown the strains rSC0012(pS-SaoA) with regulated delayed *fur* mutation could confer higher protection against challenges with lethal doses of *SS* or *S. Choleraesuis* C78–3. Thus, the use of attenuated *S. Choleraesuis* to develop a vaccine against *S. suis* will have the great potential to ease the burden of both pathogens. The regulated delayed *fur* mutation in the novel vaccine rSC0012 resulted in a well-safety, highly immunogenic, and effective vaccine in mice, this study has paved the way for testing in piglets. Our findings will aid the optimal of a *S. Choleraesuis* vaccine vector capable of eliciting a suitable immune response against other pathogens.

**Methods**

**Animals**

All animal experiments were authorized by the Jiangsu Administrative Committee for Laboratory Animals (permission number SYXK-SU–2007–0005) and accorded to the Jiangsu Laboratory Animal Welfare and Ethics guidelines of the Jiangsu Administrative Committee of Laboratory Animals. All surgery was performed under anesthesia intraperitoneally injected with sodium pentobarbital, 675 µg per mouse. All the animals were humanely euthanized after the study by inhalation of CO$_2$, while injection with sodium pentobarbital, 675 µg per mouse, and all efforts were made to minimize suffering.

**Strains, plasmids, and culture conditions**

The strains, plasmids, used in this study are described in Table 1. C500, an approved live *S. Choleraesuis* vaccine strain attenuated by thallium compound in China, was used as an attenuation control [39]. The genetic characterization of this strain has been reported [40]. *S. suis* serotype 2 (SS2, CVCC3928) and *S. Choleraesuis* C78–3 (CVCC79103) were purchased from China Institute of Veterinary Drug Control. Plasmid pYA3493 is an Asd$^+$ vector with a P$_{trc}$ promoter. The *asd* gene from *Salmonella* was used as a unique plasmid marker to be used in *asd* mutants to constitute a balanced-lethal system [18]. LB medium [5], Nutrient broth (NB) and MacConkey agar (Difco) were used for phenotype characterization. When required, media were supplemented with 2,6-diaminopimelic acid (DAP; 50 µg/mL), chloramphenicol (Cm; 25 µg/mL), L-arabinose (0.2% wt/vol), D-mannose (0.2% wt/vol) or sucrose (5% wt/vol). Plasmid pS-SaoA were described on previously study [5]. The *saoA* gene is under the control of the P$_{trc}$ promoter (Table 1). *S. Choleraesuis* vaccine vector strain rSC0012 harboring plasmid
pS-SaoA (expression vector) or pYA3493 (control vector) were grown in LB broth with both 0.2% arabinose and 0.2% mannose. Selenite broth was used for enrichment of *S. Choleraesuis* from mice tissues. Strains were prepared as previously described [5,9,10,30]. Bacterial growth was monitored with a spectrophotometer at OD$_{600}$ and by direct plating for colony counts.

**Construction of *S. Choleraesuis* mutant strains.**

Four mutations Δ$P_{fur}$::TT *araC*$_{P_{BAD}}$ *fur*, Δ$pmi$, Δ$relA$::*araC*$_{P_{BAD}}$ _lacr_ TT, and Δ$asdA$ were introduced into *S. Choleraesuis* C78–3 by conjugation with *E. coli* χ7213 harboring aforementioned suicide vectors as previously described [41]. The suicide vectors used are listed in Table 1 and Fig. 1A. To construct mutation Δ$P_{fur}$::TT *araC*$_{P_{BAD}}$ *fur*, a 1,335-bp TT *araC*$_{P_{BAD}}$ cassette was used to replace the 239-bp promoter sequence of the *fur* gene to achieve arabinose-regulated Fur synthesis (Figure 1A). The *araC*$_{P_{BAD}}$ cassette contains a transcription terminator (TT) sequence to prevent *araC* transcription reading through adjoining genes. Plasmid for Δ$P_{fur}$::TT *araC*$_{P_{BAD}}$ *fur* were confirmed by DNA sequencing. All the primers used have been reported [26].

**Characterization of *S. Choleraesuis* mutations in vitro**

All mutations were confirmed by colony PCR using homologous primers [30]. The Δ$asdA$ mutation was verified by growth with or without DAP in LB broth [18,19]. Lipopolysaccharide (LPS) profiles were examined by silver staining in 12% sodium dodecyl sulfate-polyacrylamide (SDS) gel for the Δ$pmi$ mutation [41,42]. The Δ$P_{fur}$::TT *araC*$_{P_{BAD}}$ *fur* deletion-insertion mutation was verified by reduced production of Fur protein as arabinose concentrations decreased with the increased bacterial growth by western blot using anti-Fur antiserum[30]. The production of SaoA was verified by western blot using anti-SaoA antiserum, respectively [9,18,19,20].

**Salmonella subcellular fractionation**

To evaluate the subcellular localization of synthesized SaoA in the live attenuated *S. Choleraesuis* vaccine, cultures were grown in NB to an OD$_{600}$ of 0.8 and centrifuged at 13,200 × g for 5 min to collect supernatant and pellet. The culture supernatant was saved for later analysis of the bacterial secreted proteins. Periplasmic fractions were prepared using the lysozyme-osmotic shock method as previously described [43,44]. Equal volumes of supernatant, periplasmic, cytoplasmic samples were separated by SDS-PAGE. Proteins were then transferred to polyvinylidene fluoride membrane for western blot analysis using anti-SaoA antiserum [5]. The gel band were analyzed with ImageJ software (NIH) [45].

**Preparation of SaoA and Salmonella outer membrane proteins (SOMPs)**

His-tagged SaoA fusion protein and *Salmonella* outer membrane proteins (SOMPs) were prepared as previous described [5].

**Determination of virulence in mice.**
Three-week-old female BALB/c mice were obtained from Animal Center of Yangzhou University. Mice were fasting for 6 h before inoculation. Recombination S. Choleraesuis vector strains were cultured in LB broth with D–0.2% mannose and 0.2% L-arabinose for 12 hours at 37°C as standing cultures. The cultures were diluted 1:50 in the same media and cultured at 37°C to an OD$_{600}$ of 0.9. Bacteria were collected by centrifugation at 13,200 × g for 5 min at room temperature and resuspended in PBS to densities suitable for the inoculation. Serial dilutions of the S. Choleraesuis strains were plated onto LB agar supplemented with 0.2% D-mannose and 0.2% L-arabinose to measure the actual densities. Groups of five mice were inoculated with different doses in 20 μl (oral immunization) or 100 μl (intraperitoneal immunization). The mice were observed for 4 weeks for death. The LD$_{50}$s were calculated according the method of Reed and Muench [46].

**Distribution of Salmonella in BALB/c mice**

A colonization assay for recombination S. Choleraesuis vector strains was performed as described previously [9, 11]. Three-week-old female BALB/c mice were divided into 7 groups with 25 mice in each group. Each mouse was orally inoculated with 1±0.2×10$^9$ CFU of S. Choleraesuis strains. Peyer's patches, spleen, and liver of the mice were collected on days 3, 7, 14, 21 and 28 post-inoculated. The densities of bacteria in the tissues were determined using the method reported in previous studies [5, 9, 11, 47]. The assay was performed twice, and the data were similar and pooled for analysis.

**Immunization of mice**

Bacteria were grown and collected as above. Serial dilutions of the S. Choleraesuis vaccine strains were plated onto LB agar supplemented with 0.2% D-mannose and 0.2% L-arabinose to determine the actual dose. Three-week-old female BALB/c mice were orally inoculated with 1±0.2×10$^9$ CFU of S. Choleraesuis vaccine strains containing either pS-SaoA or pYA3493. Mice were boosted inoculated with the same dose of the same strain after three weeks. About 50 μL of whole blood was collected by tail vein three weeks after primary inoculation and two weeks after boosting. Serum was separated from the whole-blood samples and stored at −70°C. Vaginal-wash samples in mice were collected at the indicated time and stored at −70 °C [9, 35, 48, 49]. This experiment was performed in triplicate with each group receiving a similar dose of the vaccine strains.

**Tissue collection after Salmonella infection of mice**

Three-week-old female BALB/c mice were divided into 5 groups with 10 mice in each group. Groups of mice were orally inoculated with 1±0.3×10$^9$ CFU of *Salmonella* strains. Spleen and intestinum tenue of the mice were collected at 6 h and 12 h postinfection. The tissues were frozen with liquid nitrogen and then transferred to −70°C.

**Enzyme-linked immunosorbent assay (ELISA)**
Serum IgG antibody production against *S. Choleraesuis* outer membrane proteins (OMPs) and SS2 SaoA, and vaginal-wash IgA antibody production against SaoA in mice were evaluated by Enzyme-linked immunosorbent assay (ELISA) [5]. Cytokines in tissues were analyzed by sandwich ELISA using commercial kits (BD Biosciences) according to manufacturer's instructions. The results from the two experiments were pooled for statistical analysis.

*Quantitative real-time PCR (qPCR) for cytokines*

For RNA isolation, gut tissues were homogenized and suspended in TRIzol® (Thermo Fisher Scientific, USA). Tubes were vortexed for 3 min to disrupt the tissues. Chloroform was added to TRIzol®-treated samples and the samples centrifuged at 13200×g for 10 min. The aqueous phase was separated out, and the RNA precipitated using precooled isopropanol. For quantitative real-time PCR, 1 μg of RNA was then reverse transcribed to cDNA. The primers were designed using Primer Blast (NCBI net) and synthesized by TSINGKE Biological Technology Co., Ltd. The sequences of the primers are listed in Table 3. Each sample were amplified using 7500 Fast Real-Time PCR Instrument (ABI, US) using Fast SYBR Green Master Mix (Thermo-Fisher Scientific). The results were using internal reference GAPDH as control for normalization, and the $2^{-\Delta\Delta Ct}$ method was used to estimate the relative expression level of the mRNAs of target genes.

*Challenge with *S. suis* serotype 2 (SS2) and *S. Choleraesuis* (C78–3) in mice*

Twenty mice in each group were challenged with SS2 by intraperitoneal (i.p.) injection with $2.4 \times 10^8$ CFU of SS2 in 100 μl PBS at five weeks after primary immunization. The 50% lethal dose (LD$_{50}$) of SS2 in BALB/c mice was $1.2 \times 10^7$ CFU. Another twenty mice in each group were challenged orally with $4.8 \times 10^4$ CFU of C78–3 in 20 μl PBS. The LD$_{50}$ of C78–3 in 3-week-old BALB/c mice was $9.5 \times 10^2$ CFU. Challenged mice were monitored for death daily for 15 days [9, 25, 26, 35].

*Statistical analysis*

Statistical analyses on ELISA were presented as the geometric means and standard deviations for all assays. A Mann-Whitney U Test (GraphPad Software, Inc.) was applied to contrasting the distribution of the *S. Choleraesuis* in tissues of mice. The Kaplan-Meier method (SPSS Software) was used for obtain the survival fractions following i.p. challenge of immunized mice. A $P$ value of 0.05 was considered statistically significant.

*Abbreviations*

*Salmonella enterica* serotype Choleraesuis: S.Choleraesuis, *Streptococcus suis*: S. suis, Sao: Surface-anchored protein, SS2: S. suis serotype 2, RDAS: Regulated delayed attenuated strategies, LB: Luria broth, LD50: 50% lethal dose. Antigen-Presenting Cells: APC; Major Histocompatibility Complex®: MHC®, T helper type 1: Th1; Phosphate buffer saline: PBS; Lipopolysaccharide: LPS; Sodium dodecyl sulfate-polyacrylamide: SDS.
Declarations

Ethics approval and consent to participate

Procedures involving the care and use of animals were approved by the Jiangsu Administrative Committee for Laboratory Animals (permission number SYXK-SU–2007–0005) and complied with the Jiangsu Laboratory Animal Welfare and Ethics guidelines of the Jiangsu Administrative Committee of Laboratory Animals.

Consent for publication

Not applicable.

Availability of data and material

All data generated or analysed during this study will be available from the corresponding author on reasonable request.

Competing interests

None of the authors of this manuscript have any competing or financial interests.

Funding

This work was supported by the National Natural Science Foundation of China (31172300, 31672516), supported by the Grant No. BE2016343 from Jiangsu province and the Priority Academic Program Development of Jiangsu Higher Education Institutions, supported by State Key Laboratory of Genetically Engineered Veterinary Vaccines (No.AGVSKL-ZD/ZY–201807). The funding bodies have not been involved in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors’ contributions

Design of the study: YA-L, HY-S and SF-W. Performed experiments: YA-L, YY-C, YZ-D, WW-G, J-F. Wrote the manuscript: YA-L, MB, SF-W. All authors have read and approved the manuscript.

Acknowledgements

The authors thank to Dr. Curtiss, III for kindly providing χ7213, pRE112, pYA3493, and the antibody of Fur.

References

[1] Seele J, Hillermann L M, Beineke A, et al. The immunoglobulin M-degrading enzyme of Streptococcus suis, IdeSsuis, is a highly protective antigen against serotype 2[J]. Vaccine, 2015, 33(19):2207–2212.
[2] The protective protein Sao (surface antigen one) is not a critical virulence factor for Streptococcus suis serotype 2[J]. Microbial Pathogenesis, 2014, 67–68:31–35.

[3] Li Y, Martinez G, Gottschalk M, et al. Identification of a Surface Protein of Streptococcus suis and Evaluation of Its Immunogenic and Protective Capacity in Pigs[J]. Infection and Immunity, 2006, 74(1):305–312.

[4] Li Y, Gottschalk M, Esgleas M, et al. Immunization with Recombinant Sao Protein Confers Protection against Streptococcus suis Infection[J]. Clinical and Vaccine Immunology, 2007, 14(8):937–943.

[5] Li Y A, Ji Z, Wang X, et al. Salmonella enterica serovar Choleraesuis vector delivering SaoA antigen confers protection against Streptococcus suis serotypes 2 and 7 in mice and pigs[J]. Veterinary Research, 2017, 48(1):89.

[6] Curtiss R, Wanda S Y, Gunn B M, et al. Salmonella enterica Serovar Typhimurium Strains with Regulated Delayed Attenuation In Vivo[J]. Infection and Immunity, 2009, 77(3):1071–1082.

[7] Collins L V, Attridge S,, Hackett J. Mutations at rfc or pmi attenuate Salmonella typhimurium virulence for mice[J]. Infection & Immunity, 1991, 59(3):1079–1085.

[8] Li Y, Wang S, Scarpellini G, et al. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA[J]. Proceedings of the National Academy of Sciences, 2009, 106(2):593–598.

[9] Ji Z, Shang J, Li Y, et al. Live attenuated Salmonella enterica serovar Choleraesuis vaccine vector displaying regulated delayed attenuation and regulated delayed antigen synthesis to confer protection against Streptococcus suis in mice[J]. Vaccine, 2015.

[10] Curtiss R, Wanda S Y, Gunn B M, et al. Salmonella enterica Serovar Typhimurium Strains with Regulated Delayed Attenuation In Vivo[J]. Infection and Immunity, 2009, 77(3):1071–1082. [31] Foster J W, Hall H K. Effect of Salmonella typhimurium ferric uptake regulator (fur) mutations on iron- and pH-regulated protein synthesis.[J]. Journal of Bacteriology, 1992, 174(13):4317–4323.

[11] Riesenbergwilmes M R, Bearson B, Foster J W, et al. Role of the acid tolerance response in virulence of Salmonella typhimurium.[J]. Infection & Immunity, 1996, 64(4):1085–92.

[12] Tsolis R M, A J Bäumler, Stojiljkovic I, et al. Fur regulon of Salmonella typhimurium: Identification of new iron- regulated genes[J]. Journal of Bacteriology, 1995, 177(16):4628–4637.

[13] Troxell B, Hassan H M. Transcriptional regulation by Ferric Uptake Regulator (Fur) in pathogenic bacteria[J]. Frontiers in Cellular and Infection Microbiology, 2013, 3.

[14] Choi E, Kim H, Lee H, et al. The Iron-Sensing Fur Regulator Controls Expression Timing and Levels of Salmonella Pathogenicity Island 2 Genes in the Course of Environmental Acidification[J]. Infection and
[15] Juarez-Rodriguez M D, Yang J, Kader R, et al. Live Attenuated Salmonella Vaccines Displaying Regulated Delayed Lysis and Delayed Antigen Synthesis To Confer Protection against Mycobacterium tuberculosis[J]. Infection and Immunity, 2012, 80(2):815–831.

[16] Wang S, Li Y, Scarpellini G, et al. Salmonella Vaccine Vectors Displaying Delayed Antigen Synthesis In Vivo To Enhance Immunogenicity[J]. Infection and Immunity, 2010, 78(9):3969–3980.

[17] Wang S, Li Y, Shi H, et al. Comparison of a Regulated Delayed Antigen Synthesis System with In Vivo-Inducible Promoters for Antigen Delivery by Live Attenuated Salmonella Vaccines[J]. Infection and Immunity, 2011, 79(2):937–949.

[18] Galán, Jorge E, Nakayama K, Curtiss R. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains[J]. Gene (Amsterdam), 1990, 94(1):29–35.

[19] Nakayama K, Kelly S M, Curtiss R. Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a Salmonella Vaccine Strain[J]. Nature Biotechnology, 1988, 6(6):693–697.

[20] Zhao Z, Xue Y, Wu B, Tang X, Hu R, Xu Y, Guo A, Chen H. Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bordetella bronchiseptica[J]. Infect Immun, 2008 76:2157–2163

[21] Zhang X, Kelly S M, Bollen W S, et al. Characterization and immunogenicity of Salmonella typhimurium SL1344 and UK–1 delta-crp and delta-cdt deletion mutants[J]. Infection & Immunity, 1997, 65(12):5381.

[22] Curtiss R III. New Antigen delivery systems: Development of live recombinant attenuated bacterial antigen and DNA vaccine delivery vector vaccines. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee J, Mayer L. editors. Mucosal Immunology. 2005. pp. 1009–1037.

[23] Salerno-Goncalves R, Sztein MB, Pasetti MF, Levine MM, Tennant SM. Improved Tolerability of a Salmonella enterica Serovar Typhimurium Live-Attenuated Vaccine Strain Achieved by Balancing Inflammatory Potential with Immunogenicity[J]. Infection and Immunity, 2018, DOI: 10.1128/IAI.00440–18

[24] Gunn B M, Wanda S Y, Burshell D, et al. Construction of Recombinant Attenuated Salmonella enterica Serovar Typhimurium Vaccine Vector Strains for Safety in Newborn and Infant Mice[J]. Clinical and Vaccine Immunology, 2010, 17(3):354–362.
[25] Li Y, Wang S, Xin W, et al. A sopB Deletion Mutation Enhances the Immunogenicity and Protective Efficacy of a Heterologous Antigen Delivered by Live Attenuated Salmonella enterica Vaccines[J]. Infection and immunity, 2008, 76(11):5238–5246.

[26] Gunn B M, Wanda S Y, Burshell D, et al. Construction of Recombinant Attenuated Salmonella enterica Serovar Typhimurium Vaccine Vector Strains for Safety in Newborn and Infant Mice[J]. Clinical and Vaccine Immunology, 2010, 17(3):354–362.

[27] Karasova D, Sebkova A, Vrbas V, et al. Comparative analysis of Salmonella enterica serovar Enteritidis mutants with a vaccine potential[J]. Vaccine, 2009, 27(38):0–5270.

[28] Foster J W, Hall H K. Effect of Salmonella typhimurium ferric uptake regulator (fur) mutations on iron- and pH-regulated protein synthesis.[J]. Journal of Bacteriology, 1992, 174(13):4317–4323.

[29] Riesenbergwilmes M R, Bearson B, Foster J W, et al. Role of the acid tolerance response in virulence of Salmonella typhimurium.[J]. Infection & Immunity, 1996, 64(4):1085–92.

[30] Huoying S, Javier S, Brenneman K E, et al. Live Recombinant Salmonella Typhi Vaccines Constructed to Investigate the Role of rpoS in Eliciting Immunity to a Heterologous Antigen[J]. PLoS ONE, 2010, 5(6):e11142.

[31] Troxell B, Hassan H M. Transcriptional regulation by Ferric Uptake Regulator (Fur) in pathogenic bacteria[J]. Frontiers in Cellular and Infection Microbiology, 2013, 3.

[32] Galen J E, Curtiss R. The delicate balance in genetically engineering live vaccines[J]. Vaccine, 2014, 32(35):4376–4385.

[33] Tsolis R M, A J Bäumler, Stojilkovic I, et al. Fur regulon of Salmonella typhimurium: Identification of new iron-regulated genes[J]. Journal of Bacteriology, 1995, 177(16):4628–4637.

[34] Choi E, Kim H, Lee H, et al. The Iron-Sensing Fur Regulator Controls Expression Timing and Levels of Salmonella Pathogenicity Island 2 Genes in the Course of Environmental Acidification[J]. Infection and Immunity, 2014, 82(6):2203–2210.

[35] Shi H, Wang S, Curtiss R. Evaluation of Regulated Delayed Attenuation Strategies for Salmonella Typhi Vaccine Vectors in Neonatal and Infant Mice[J]. Clinical & Vaccine Immunology Cvi, 2013, 20(6):931–944.

[36] Kong Q, Liu Q, Jansen A M, et al. Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines[J]. Vaccine, 2010, 28(37):0–6103.

[37] Zhu L, Zhao X, Yin Q, et al. Mucosal IgA and IFN-γ+ CD8 T cell immunity are important in the efficacy of live Salmonella enteria serovar Choleraesuis vaccines.[J]. Scientific Reports, 2017, 7:46408.
[38] Ministry of Agriculture C. The People's Republic of China veterinary biological product regulation. Chemical Industry Publishing Company, Beijing, China, 2000: 164–166

[39] Zhao Z, Xue Y, Wu B, Tang X, Hu R, Xu Y, Guo A, Chen H. Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bordetella bronchiseptica [J]. Infect Immun, 2008 76: 2157–2163

[40] Li Q, Hu Y, Xu L, et al. Complete Genome Sequence of Salmonella enterica Serovar Choleraesuis Vaccine Strain C500 Attenuated by Chemical Mutation [J]. Genome Announcements, 2014, 2(5): e01022–14–e01022–14.

[41] Tsai C M, Frasch C. A sensitive silver stain for detecting lipooligosaccharide in polyacrylamide gels [J]. Analytical Biochemistry, 1981, 199: 115–119.

[42] Hitchcock P. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels [J]. J Bacteriol, 1983, 154.

[43] Witholt B, Boekhout M, Brock M, et al. An efficient and reproducible procedure for the formation of spheroplasts from variously grown Escherichia coli [J]. Analytical Biochemistry, 1976, 74(1): 160–170.

[44] Kang, H. Y. Immune Responses to Recombinant Pneumococcal PspA Antigen Delivered by Live Attenuated Salmonella enterica Serovar Typhimurium Vaccine [J]. Infection and Immunity, 2002, 70(4): 1739–1749.

[45] Schindelin J, Rueden C T, Hiner M C, et al. The ImageJ ecosystem: An open platform for biomedical image analysis [J]. Molecular Reproduction and Development, 2015, 82(7–8): 518–529.

[46] Reed L J. A simple method of estimating fifty per cent endpoints [J]. Am. J. Hyg. 1938, 27.

[47] Rd C S. CHROMOSOMAL ABERRATIONS ASSOCIATED WITH MUTATIONS TO BACTERIOPHAGE RESISTANCE IN ESCHERICHIA COLI. [J]. Journal of Bacteriology, 1965, 89(1): 28.

[48] Xinxin Z, Sheng L, Qinlong D, et al. Regulated delayed attenuation enhances the immunogenicity and protection provided by recombinant, Salmonella, enterica, serovar Typhimurium vaccines expressing serovar Choleraesuis O-polysaccharides [J]. Vaccine, 2018, 36(33): 5010–5019.

[49] Wang S, Li Y, Scarpellini G, et al. Salmonella Vaccine Vectors Displaying Delayed Antigen Synthesis In Vivo To Enhance Immunogenicity [J]. Infection and Immunity, 2010, 78(9): 3969–3980.

[50] Kang H Y, Dozois C M, Tinge S A, et al. Transduction-Mediated Transfer of Unmarked Deletion and Point Mutations through Use of Counterselectable Suicide Vectors [J]. Journal of Bacteriology, 2002, 184(1): 307–312.
Tables

Table 1. Strains and plasmids
| Strain or plasmid | Relevant characteristics or genotype | Source or reference |
|------------------|--------------------------------------|---------------------|
| **E. coli strains** |                                       |                     |
| BL21             | F<sup>-</sup> pT hsdSB(rB<sup>-</sup> mB<sup>-</sup>al dcm) (DE3) | Invitrogen          |
| χ7213            | thi-1 thr-1 leuB6 fhuA21 lacY1 glnV44 asdA4 recA1 RP4 2-Tc::Mu pir; Km<sup>+</sup> | Gift from Dr. Curtiss, III |
| **Salmonella Choleraesuis** |                                       |                     |
| C78-3            | Wild type, virulent, CVCC79103        | Lab stock           |
| C500             | S. Choleraesuis vaccine strain attenuated by chemical mutation, CVCC79500 | [40]                |
| rSC0005          | Δpmi-2426, C78-3                      | [9]                 |
| rSC0008          | Δpmi-2426 ΔrelA199::araC<sub>BAD</sub> lacI TT | This study          |
| rSC0009          | Δpmi-2426 ΔrelA199::araC<sub>BAD</sub> lacI TT | This study          |
|                  | ΔP<sub>fur88</sub>::TT araC<sub>BAD</sub> fur |                     |
| rSC0011          | ΔP<sub>crp527</sub>::TT araC<sub>BAD</sub> crp Δpmi-2426 ΔrelA199::araC<sub>BAD</sub> lacI TT ΔasdA33 | [9]                 |
| rSC0012          | Δpmi-2426 ΔrelA199::araC<sub>BAD</sub> lacI TT | This study          |
|                  | ΔP<sub>fur88</sub>::TT araC<sub>BAD</sub> fur ΔasdA33 |                     |
| rSC0018          | ΔasdA33                               | C500                |
|                  | C78-3 ΔP<sub>fur88</sub>::TT araC<sub>BAD</sub> fur | C78-3               |
|                  | C78-3 ΔP<sub>crp527</sub>::TT araC<sub>BAD</sub> crp | C78-3               |
| **Streptococcus suis serotype 2** |                                       |                     |
|                  | Wild type, virulent, CVCC3928         | Lab stock           |
| **Plasmids**     |                                       |                     |
| pYA3493          | Asd<sup>+</sup>; pBR ori, P<sub>trc</sub> promoter, β-lactamase signal sequence-based periplasmic secretion plasmid | [19]                |
| pS-SaoA          | pYA3493 with SaoA, P<sub>trc</sub> promoter | [5]                 |
pET28a expression vector, T7 promoter; Km\(^r\) Novagen

Suicide vector

pRE112 \(\text{sacB mobRP4 R6K oriV oriT Cm}^r\) [50]
pDMS197 \(\text{tet}^r\text{sacB mobRP4 R6K oriV oriT}\) [50]
pYA3832 \(\Delta P_{\text{crp527}}::\text{TT araC} \_P_{\text{BAD}} \text{crp}, \text{pRE112}\) [46]
pYA3546 \(\Delta pmi-2426, \text{pDMS197}\) [46]
pS003 \(\Delta \text{relA199::araC} \_P_{\text{BAD}} \text{lacI TT}, \text{pRE112}\) [9]
pS005 \(\Delta P_{\text{fur88}}::\text{TT araC} \_P_{\text{BAD}} \text{fur}\) This study
pYA3736 \(\Delta \text{asdA33, pRE112}\) [9]

Table 2. Virulence of rSC0012(pS-SaoA) in 3-week-old BALB/c mice

| Strain          | Description                                      | LD\(_{50}\) (CFU) | Oral | i.p  |
|-----------------|--------------------------------------------------|-------------------|------|------|
| C78-3           | Wild type                                        | 9.5\(\times\)10\(^2\) | 9.5\(\times\)10\(^2\) | <10  |
| rSC0018(pS-SaoA)| \(\Delta \text{asdA33 in a live attenuated S. Choleraesuis}\) vaccine strain C500 | >2.8\(\times\)10\(^9\) | 6.6\(\times\)10\(^6\) **,## | 6.6\(\times\)10\(^6\) **,## |
| rSC0012(pS-SaoA)| \(\Delta P_{\text{fur88}}::\text{TT araC} \_P_{\text{BAD}} \text{fur} \Delta pmi-2426\) | >5.8\(\times\)10\(^9\) ** | 2.1\(\times\)10\(^7\) **,## | 2.1\(\times\)10\(^7\) **,## |
| rSC0011(pS-SaoA)| \(\Delta P_{\text{crp527}}::\text{TT araC} \_P_{\text{BAD}} \text{crp} \Delta pmi-2426\) \(\Delta \text{relA199::araC} \_P_{\text{BAD}} \text{lacI TT} \Delta \text{asdA33 in C78-3}\) | >1.0\(\times\)10\(^9\) ** | 5.4\(\times\)10\(^5\) ** | 5.4\(\times\)10\(^5\) ** |

**, \(P<0.01\), compared with C78-3; ##, \(P<0.01\), compared with rSC0011(pS-SaoA)

Table 3 Primer sequences
| Gene   | Sequence  | 5′-3′ |
|-------|-----------|-------|
| GAPDH | Forward   | CTT AGC ACC CCT GGC CAA G |
|       | Reverse   | GAT GTT CTG GAG AGC CCC G |
| IL-1β | Forward   | GTG TCT TTC CCG TGG ACC TT |
|       | Reverse   | AAT GGG AAC GTC ACA CAC CA |
| IL-6  | Forward   | GGC GGA TCG GAT GTT GTG AT |
|       | Reverse   | GGA CCC CAG ACA ATC GGT TG |
| TNF-α | Forward   | ATG AGC ACA GAA AGC ATG A |
|       | Reverse   | AAG AGG CTG AGA CAT AGG C |
| IL-8  | Forward   | CTG CAA GAG ACT TCC ATC CAG |
|       | Reverse   | AGT GGT ATA GAC AGG TCT GTT GG |

**Figures**
Diagram of chromosomal mutation and phenotypes of the S. Choleraesuis vaccine strain rSC0012. (A) Schematic map of ΔPfur::TT araC PBAD fur deletion - insertion mutation; (B) Regulated decreased synthesis of Fur (ΔPfur::TT araC PBAD fur) and regulated delayed synthesis of SaoA in rSC0012(pS-SaoA) with the ΔrelA::araC PBAD lacI TT mutation. The rSC0012(pS-SaoA) strain was grown in NB with arabinose (Lane 1) when OD600 reach 0.8 and then diluted at a 1:10 ratio into fresh NB without arabinose. The process continued for 4 times (Lane 2 - 5); each lane was loaded around 4.6 × 10^7 CFU cells. Synthesis of Fur and SaoA were detected by western blot using corresponding antiserum. M: protein marker; (C) LPS profile of Δpmi mutation in rSC0012 in NB grown with or without 0.2% mannose. Lanes: 1, wild type C78-3; 2, C500; 3, rSC0012 with mannose; 4, rSC0012 without mannose; (D) Growth curves of rSC0012 with and without DAP, rSC0012(pYA3493) or rSC0012(pS-SaoA) in LB were measured with a spectrophotometer (OD600) at the indicated time intervals.
Figure 2

Synthesis of SaoA in Salmonella Choleraesuis vector rSC0011, rSC0012 and rSC0018. (A) Subcellular fractions of SaoA in rSC0011(pS-SaoA), rSC0012(pS-SaoA), and rSC0018(pS-SaoA) from cells grown in NB detected by western blot. The number showed relative densitometry in one of the three representative experiments. (B) Densitometry analysis of the SaoA protein in rSC0011(pS-SaoA), rSC0012(pS-SaoA), and rSC0018(pS-SaoA) by using Image J software (Image J2 PMID 26153368). The assay was repeated
Figure 3

Colonization of Salmonella Choleraesuis rSC0012 in BALB/c mice at different time points. Mice were orally inoculated with $1.0 \pm 0.3 \times 10^9$ CFU of the indicated strains. The numbers of bacteria loads in the Peyer’s patches (A), spleen (B) and liver (C) of mice at 3 d, 7 d, 14 d, 21 d and 28 d after inoculation were measured.
plotted. Bars represent the arithmetic mean ± standard deviations from two separate experiments each with 5 mice per group. *, P<0.05; **, P < 0.01, for rSC0018 compared to rSC0012 or to rSC0011 with either pYA3493 or pS-SaoA; #, P<0.05, ##, P < 0.01, for rSC0011 compared to rSC0012 or to rSC0011 with either pYA3493 or pS-SaoA; $$, P < 0.01, for C78-3 compared to rSC0011, rSC0012 and rSC0018 with either pYA3493 or pS-SaoA, as indicated. The data were collected from two independent experiments.

Figure 4
Antibody responses in ten mice. Serum IgG responses to SaoA (A), S. Choleraesuis OMPs (B) and vaginal wash IgA responses to SaoA (C) were measured by ELISA at weeks 3 and 5. Each triangle represents one mouse. Error bars represent variation between mice. Significant differences were indicated. *, P<0.05; ** P< 0.01, for Salmonella carrying pS-SaoA compared to each other; #, P<0.05; ##, P< 0.01, for the titers of antibody at 3 weeks after immunization were compared to those at 5 weeks after immunization. No immune responses were detected to antigen tested in mice immunized with PBS or in pre-immune sera from vaccinated mice (reciprocal titer <1:50). The assay was performed in duplicate and repeated at least 3 times.
Figure 5

Cytokines levels in ten mice immunized with the S. Choleraesuis vaccines. IFN-γ (A) and IL-4 (B) in spleens 7 d after the booster dose were assayed with an EILSA kit. A PBS control were also included. (C) the ratio of IFN-γ to IL-4. The significant differences between groups of each strain was indicated. The assay was performed in duplicate and repeated at least 3 times. *, P<0.05; ** P < 0.01, for strains rSC0011, rSC0012, rSC0018 with either pYA3493 or pS-SaoA compared each other; #, P<0.05; ##, P <
0.01, for the strains rSC0011, rSC0012, rSC0018 with pS-SaoA compared to these strains with pYA3493 respectively at 7 d and 14 d post immunization.

**Figure 6**

Induction of inflammatory cytokines at 6 h and 12 h post-infection in ten mice immunized with different Salmonella strains. Analysis of RNA transcript levels by qPCR showed that all mutant strains induced less inflammatory cytokine production than the wild-type strain C78-3 at both 6 h (A and C) and 12 h (B and D) post-infection. &, P<0.05, C78-3 ΔPfur88 TT araC PBAD fur compared to C78-3; #, P<0.05, ##, P<0.01, rSC0012(pS-SaoA) compared to rSC0011(pS-SaoA); *, P<0.05, **, P<0.01, strains with ΔPfur88 TT araC PBAD fur mutation compared to C78-3.
Figure 7

Protection in mice. Groups of 40 mice were orally immunized twice at 3 weeks intervals with indicated strains. Half of the mice were challenged orally with 50×LD50 of C78-3 and the other half were intraperitoneally injected with 20×LD50 of SS2 at 2 weeks after the 2nd immunization.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- supplement1.doc